• Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 20.13
▲ +1.005 (5.26%)

This chart shows the closing price for HVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New hVIVO Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HVO

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for hVIVO in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 20.13.

This chart shows the closing price for HVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in hVIVO. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2018Numis SecuritiesReiterated RatingBuyGBX 100
9/20/2018Numis SecuritiesReiterated RatingBuy
9/19/2018BarclaysUpgradeOverweight
6/18/2018Numis SecuritiesReiterated RatingBuyGBX 55
6/6/2018Numis SecuritiesReiterated RatingBuyGBX 55
4/19/2018Numis SecuritiesDowngradeHoldGBX 80 ➝ GBX 55
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.08 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/8/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/7/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/6/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
hVIVO logo
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 20.13
Low: 18.80
High: 20.38

50 Day Range

MA: GBX 13.12
Low: 9.50
High: 19.13

52 Week Range

Now: GBX 20.13
Low: 9.20
High: 20.38

Volume

1,808,058 shs

Average Volume

3,147,413 shs

Market Capitalization

£135.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of hVIVO?

The following sell-side analysts have issued stock ratings on hVIVO in the last twelve months:
View the latest analyst ratings for HVO.

What is the current price target for hVIVO?

0 Wall Street analysts have set twelve-month price targets for hVIVO in the last year. has the lowest price target set, forecasting a price of £100,000 for hVIVO in the next year.
View the latest price targets for HVO.

What is the current consensus analyst rating for hVIVO?

hVIVO currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HVO.

What other companies compete with hVIVO?

How do I contact hVIVO's investor relations team?

hVIVO's physical mailing address is Q M B Innovation Centre, 42 New Road, LONDON, E1 2AX, United Kingdom. The company's listed phone number is +44-20-77561300. The official website for hVIVO is hvivo.com. Learn More about contacing hVIVO investor relations.